Bivalirudin Started during Emergency Transport for Primary PCI

2013489 citationsJournal Articlebronze Open Access

Authors

Philippe Gabríel Steg · Université Paris Cité

Arnoud W.J. van ‘t Hof · Isala

Christian W. Hamm · Kerckhoff Klinik

Peter Clemmensen · University of Copenhagen

Frédéric Lapostolle · Hôpital Avicenne

Pierre Coste · Université de Bordeaux

Jurriën M. ten Berg ·

Abstract

Bivalirudin, started during transport for primary PCI, improved 30-day clinical outcomes with a reduction in major bleeding but with an increase in acute stent thrombosis. (Funded by the Medicines Company; EUROMAX ClinicalTrials.gov number, NCT01087723.).

Topics & Keywords

Acute Myocardial Infarction Research Venous Thromboembolism Diagnosis and Management Heparin-Induced Thrombocytopenia and Thrombosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 23, pp. 2207-2217

DOI: 10.1056/nejmoa1311096

Field-Weighted Citation Impact: 49.95